Are you prepared for safety oversight, CMC/manufacturing, logistics, site readiness, rare patient pathways, long-term follow-up, and regulations? We are.
Our end-to-end development approach is built to solve your cell and gene therapy clinical research challenges, so you can move at the speed of science.
Adam Callahan brings nearly 30 years of experience and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of oncology, hematology, and cell and gene therapy products. He focuses on early engagement and development strategies, aligning medical and operational teams across global programs, and measuring performance and health across projects/programs (KPIs) to deliver exceptional experiences for our clients.
Vice President, Global Therapeutic Area Head, Oncology & Hematology
Adam Callahan - Vice President, Global Therapeutic Area Head, Oncology & Hematology
Cell and gene therapy clinical research relies on perfect orchestration of biology, patients, sites, and manufacturing. Good thing Caidya is a master conductor.
We anticipate constraints early and run a coordinated, cross-functional operating model to help you:
Cell and gene therapy development requires adaptive global regulatory strategies. We help you manage evolving and non-harmonized frameworks, align design choices early, and avoid costly redesigns and delays.
We prepare sites with specialized infrastructure, training, and operational flexibility to support complex cell and gene therapy handling, while enabling sustainable long-term follow-up models across global studies.
With end-to-end traceability, strict chain of identity, precise scheduling windows, and disciplined cold chain management, we can help protect integrity and reliability in temperature-sensitive cell and gene therapy trials.
We manage process changes over time, ensure potency and assay readiness, and maintain comparability to protect data interpretability and program continuity in evolving cell and gene therapy development.
With a suite of standardized tools, processes, plans, and technology, we support planning, start-up, and execution so you can focus on sites, patients, and science.
Our services include:
Our serious cell and gene expertise gives you critical insights that will reduce risk, increase confidence, and get your therapies to the patients who need them faster.
In the last five years alone, we’ve:
We anticipate region-specific requirements, align global and local strategies early, and design protocols that account for long-term follow-up, reducing redesign risk and supporting smoother regulatory interactions.
It means sites are fully prepared with specialized infrastructure, trained staff, clear workflows, and the flexibility to manage complex handling, dosing, and follow-up requirements.
We implement robust systems and controls to track products from collection through administration, ensuring full traceability, accurate documentation, and compliance across all sites.
We design logistics around strict temperature control and narrow scheduling windows, coordinating across sites and vendors to maintain product integrity and timely delivery.
We embed intensive safety monitoring, real-time data review, and clear escalation pathways to rapidly identify and act on emerging safety signals.
We align clinical and CMC strategies, manage process changes with appropriate controls, and ensure comparability and assay readiness to preserve data interpretability.
We use targeted feasibility, specialized site networks, and patient identification pathways that account for genetic testing, access, and long-term participation needs.
We integrate endpoint strategy with long-term follow-up planning from the outset, ensuring consistent data collection, patient retention, and regulatory alignment.
We run integrated, cross-functional teams that align clinical execution with manufacturing constraints, timelines, and change management to maintain program continuity.
We support programs across multiple phases and a range of indications, applying lessons learned to manage complexity, risk, and evolving requirements throughout development.
We navigate China-specific regulatory frameworks, data requirements, and site capabilities, aligning global strategies with local execution to support compliant and efficient trial delivery.